ProxAgen Ltd.

: Mar 28, 2017

Looking for Partnership Looking for Extra EU Funds
About Me

ProxAgen is a biotech company  devoted to the development of prototypes for human and animal bioassays and vaccines.

ProxAgen commitment includes all the activities that combine basic research, applied technologies for the development of new diagnostic assay and vaccine prototypes, as well as all the pre-clinical and clinical studies necessarily for the validation of the developed products, and the exploitation of the industrial performance

Technological platforms available at ProxAgen:

-Immunobioinformatic facilities for T and B cell epitope selection on genome scale

-Identification of alternative read-out system for B- and T-cell analysis

-Develop diagnostic tools for infectious (Tuberculosis, HIV, HBV and Ebola virus) and other immune-related diseases.

-Biological sample banking and immunological testing

From early research to later-stage immunodiagnostic and vaccine development processes, ProxAgen addresses novel ways of reducing costs and greatly accelerating the R&D process by means of the integration of immunOMIC sciences, procedures and pre-industrial development.

Specialties: Immunology, In vitro studies, In vivo studies, Antigens, Antibodies, Immunological tests, ELISA, LFIC, Flow cytometry, T-cell assays, ELISpot, Immunoinformatic, Molecular modelling, Protein-Protein interaction, Epitope mapping, Epitope identification, Diagnostic test, Immunodiagnostic test, Infectious diseases, Tuberculosis, HIV, Hepatitis, Ebola virus.


Industry: Biotechnology

Type: Privately Held

Headquarter: 63, Shipchenski Prohod, 1574, Sofia (Bulgaria)

Company Size: 1-10 employees

Year of Foundation: 2009

Keywords and matching areas:

 Animal Health and Welfare
 Health Care
 Medical equipment
 Biological Sciences
 Innovation & Research
 Medical Biotechnology
 Project Management

Ideas in Progress

Favourite Calls
No Favourite calls!